Gray peptide vendors embrace stablecoins as safety fears deepen

Chainalysis said off-label peptide sales have climbed past a $100 million annual run rate, with first-quarter sales in 2026 reaching $32 million — up 159% from $12 million in the prior quarter. The blockchain analytics firm linked the surge to rising public interest in peptides and the mainstream discussion around GLP-1 drugs such as Ozempic and Wegovy, which has driven demand for cheaper, unregulated alternatives from overseas suppliers.

Faced with limits from traditional banks and card processors on transactions tied to prescription-grade and unregulated compounds, many vendors have turned to cryptocurrency to handle payments outside normal financial channels. Chainalysis described the trade as a gray market served largely by overseas suppliers, noting that Chinese chemical manufacturers now account for much of the supply.

Top vendors have developed a more organized approach to crypto payments, often using both bitcoin and stablecoins.

China

peptides, stablecoins, chainalysis, gray market, glp-1, ozempic, wegovy, bitcoin, chinese manufacturers, cryptocurrency payments